Oxford & AstraZeneca pause COVID-19 trial as participant falls ill
Phase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read more
Infectious Diseases
Lilly starts Phase 3 Trial of monoclonal antibody for COVID-19 prevention
Eli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read more
Sanofi and GSK progress talks with EU for 300 million COVID-19 vaccines
Sanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read more
Oxford & AstraZeneca COVID-19 vaccine triggers immune response
Results from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read more
U.K. buys 90 Million Pfizer, BioNTech and Valneva COVID-19 Vaccines
The United Kingdom has signed and finalised the negotiations for the procurement of 90 million doses of vaccines in development
Read more
Moderna’s mRNA COVID-19 vaccine generates antibodies in Phase I trial
Moderna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read more
Russia’s Sechenov University claims world’s first COVID-19 vaccine
At a time when pharma and biotech companies worldwide are racing to develop a vaccine, researchers at the University of
Read more
Sanofi and GSK close to reaching $624 Million U.K. Vaccine Deal
Sanofi and GlaxoSmithKline are close to reaching a 500 million-pound ($624 million) deal to supply the United Kingdom government with
Read more
Tesla to help COVID-19 vaccine developer CureVac with molecule printers
Tesla Inc is engineering mobile molecule printers to help produce the future COVID-19 vaccine developed by CureVac in Germany, the
Read more
WHO declares second deadliest DR Congo Ebola outbreak is over
The World Health Organization (WHO) and the Democratic Republic of Congo (DRC) government announced on June 25 that the second-largest
Read more